# EDGAR Filing Document

**Accession Number:** 0001944285
**File Stem:** 0001145549-25-047656
**Filing Date:** 2025-7
**Character Count:** 27208
**Document Hash:** 44957af94718e27ea12e7eab4fdfe9ab
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001145549-25-047656.hdr.sgml**: 20250724

**ACCESSION NUMBER**: 0001145549-25-047656

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250531

**FILED AS OF DATE**: 20250724

**DATE AS OF CHANGE**: 20250724

**PERIOD START**: 20260228

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tema ETF Trust
- **CENTRAL INDEX KEY:** 0001944285

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-23823
- **FILM NUMBER:** 251147741

**BUSINESS ADDRESS:**
- **STREET 1:** 1919 M STREET, N.W., SUITE 700
- **CITY:** WASHINGTON
- **STATE:** DC
- **ZIP:** 20036
- **BUSINESS PHONE:** 3024994928 EXT. 801

**MAIL ADDRESS:**
- **STREET 1:** 1919 M STREET, N.W., SUITE 700
- **CITY:** WASHINGTON
- **STATE:** DC
- **ZIP:** 20036

## Series and Classes Contracts Data

### Tema Neuroscience and Mental Health ETF (Series ID: S000081543)

| Class ID   | Class Name                              | Ticker Symbol   |
|:---|:---|:---|
| C000244457 | Tema Neuroscience and Mental Health ETF | MNTL            |

## Nport-Ex

---

| | | |
|:---|:---|:---|
| **Tema Neuroscience and Mental Health ETF** | **Tema Neuroscience and Mental Health ETF** | **Tema Neuroscience and Mental Health ETF** |
| **Schedule of Investments** | **Schedule of Investments** | **Schedule of Investments** |
| **May 31, 2025 (Unaudited)** | **May 31, 2025 (Unaudited)** | **May 31, 2025 (Unaudited)** |
| **COMMON STOCKS - 97.6%** | **Shares** | **Value**  |
| **Biotechnology - 65.0%<sup>(a)</sup>** | **Biotechnology - 65.0%<sup>(a)</sup>** | |
| ACADIA Pharmaceuticals, Inc. <sup>(b)</sup> | 10596 | $228556 |
| Alkermes PLC <sup>(b)</sup> | 5940 | 181824 |
| Alnylam Pharmaceuticals, Inc. <sup>(b)</sup> | 1982 | 603638 |
| Argenx SE - ADR <sup>(b)</sup> | 890 | 510201 |
| Avidity Biosciences, Inc. <sup>(b)</sup> | 5392 | 167044 |
| Biogen, Inc. <sup>(b)</sup> | 2501 | 324605 |
| Biohaven Ltd. <sup>(b)</sup> | 3831 | 56737 |
| Catalyst Pharmaceuticals, Inc. <sup>(b)</sup> | 11352 | 283346 |
| Crinetics Pharmaceuticals, Inc. <sup>(b)</sup> | 13066 | 398644 |
| Day One Biopharmaceuticals, Inc. <sup>(b)</sup> | 11305 | 72126 |
| Denali Therapeutics, Inc. <sup>(b)</sup> | 15174 | 200904 |
| Dyne Therapeutics, Inc. <sup>(b)</sup> | 4717 | 56415 |
| Immunovant, Inc. <sup>(b)</sup> | 5866 | 87110 |
| Intellia Therapeutics, Inc. <sup>(b)</sup> | 7677 | 52741 |
| Ionis Pharmaceuticals, Inc. <sup>(b)</sup> | 8318 | 278736 |
| Neurocrine Biosciences, Inc. <sup>(b)</sup> | 3904 | 480270 |
| Praxis Precision Medicines, Inc. <sup>(b)</sup> | 1055 | 40670 |
| Prothena Corp. PLC <sup>(b)</sup> | 6351 | 29151 |
| PTC Therapeutics, Inc. <sup>(b)</sup> | 3124 | 151577 |
| Regeneron Pharmaceuticals, Inc. | 1284 | 629520 |
| Sarepta Therapeutics, Inc. <sup>(b)</sup> | 1943 | 73057 |
| Scholar Rock Holding Corp. <sup>(b)</sup> | 4836 | 140292 |
| Solid Biosciences, Inc. <sup>(b)</sup> | 8649 | 27763 |
| Vertex Pharmaceuticals, Inc. <sup>(b)</sup> | 2298 | 1015831 |
| Voyager Therapeutics, Inc. <sup>(b)</sup> | 14960 | 40990 |
| Xenon Pharmaceuticals, Inc. <sup>(b)</sup> | 6111 | 176302 |
|  |  | 6308050 |
| **Health Care Equipment & Supplies - 11.8%** | **Health Care Equipment & Supplies - 11.8%** |  |
| Dexcom, Inc. <sup>(b)</sup> | 2231 | 191420 |
| Medtronic PLC | 2976 | 246948 |
| Penumbra, Inc. <sup>(b)</sup> | 617 | 164721 |
| Siemens Healthineers AG <sup>(c)</sup> | 2495 | 131958 |
| Stryker Corp. | 798 | 305347 |
| Sysmex Corp. | 6108 | 103254 |
|  |  | 1143648 |
| **Health Care Providers & Services - 3.2%** | **Health Care Providers & Services - 3.2%** |  |
| Acadia Healthcare Co., Inc. <sup>(b)</sup> | 2596 | 58773 |
| Option Care Health, Inc. <sup>(b)</sup> | 4975 | 162583 |
| Talkspace, Inc. <sup>(b)</sup> | 27834 | 88791 |
|  |  | 310147 |
| **Pharmaceuticals - 17.6%** | **Pharmaceuticals - 17.6%** |  |
| Arvinas, Inc. <sup>(b)</sup> | 2074 | 14933 |
| Axsome Therapeutics, Inc. <sup>(b)</sup> | 2327 | 244707 |
| Eisai Co. Ltd. | 2036 | 58592 |
| Eli Lilly & Co. | 547 | 403505 |
| Jazz Pharmaceuticals PLC <sup>(b)</sup> | 1672 | 180693 |
| Orion Oyj - Class B | 1440 | 97694 |
| Rapport Therapeutics, Inc. <sup>(b)</sup> | 1499 | 12397 |
| Teva Pharmaceutical Industries Ltd. - ADR <sup>(b)</sup> | 28861 | 484287 |
| UCB SA | 1193 | 216599 |
|  |  | 1713407 |
| **TOTAL COMMON STOCKS** (Cost $10,930,633) | **TOTAL COMMON STOCKS** (Cost $10,930,633) | 9475252 |
| **SHORT-TERM INVESTMENTS - 2.3%** | **Shares** | **Value**  |
| **Money Market Funds - 2.3%** |  |  |
| First American Treasury Obligations Fund - Class X, 4.23% <sup>(d)</sup> | 220990 | 220990 |
| **TOTAL SHORT-TERM INVESTMENTS** (Cost $220,990) | **TOTAL SHORT-TERM INVESTMENTS** (Cost $220,990) | 220990 |
| **TOTAL INVESTMENTS - 99.9% (**Cost $11,151,623**)** | **TOTAL INVESTMENTS - 99.9% (**Cost $11,151,623**)** | 9696242 |
| Other Assets in Excess of Liabilities - 0.1% | Other Assets in Excess of Liabilities - 0.1% | 14353 |
| **TOTAL NET ASSETS - 100.0%** |  | $9710595 |
| two | two | –% |
| Percentages are stated as a percent of net assets. | Percentages are stated as a percent of net assets. | –% |
| The Global Industry Classification Standard ("GICS<sup>®</sup>") was developed by and/or is the exclusive property of MSCI, Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P"). GICS<sup>®</sup> is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. | The Global Industry Classification Standard ("GICS<sup>®</sup>") was developed by and/or is the exclusive property of MSCI, Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P"). GICS<sup>®</sup> is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. | The Global Industry Classification Standard ("GICS<sup>®</sup>") was developed by and/or is the exclusive property of MSCI, Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P"). GICS<sup>®</sup> is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. |

---

ADR - American Depositary Receipt <br> PLC - Public Limited Company

(a) To the extent that the Fund invests more heavily in a particular industry or sector of the economy, its performance will be especially sensitive to developments that significantly affect those
 industries or sectors.

(b) Non-income producing security.

(c) Security is exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may only be resold in transactions exempt from registration to qualified
 institutional investors. As of May 31, 2025, the value of these securities total $131,958 or 1.4% of the Fund's net assets.

(d) The rate shown represents the 7-day annualized effective yield as of May 31, 2025.

------

#### Tema ETF Trust

#### Tema Neuroscience and Mental Health ETF
Notes to Quarterly Schedule of Investments

May 31, 2025 (Unaudited)

#### Investment Valuation
The Fund discloses the fair value of their investments in a hierarchy that distinguishes between: (1) market participant assumptions developed based on market data obtained from sources independent of the Fund's (observable inputs) and (2) the Fund's own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:

**• Level 1** — Quoted prices in active markets for identical assets that the Fund's have the ability to access.

**• Level 2** — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).

**• Level 3** — Significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used to value the Fund's investments as of May 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **<u>Level 1</u>** | **<u>Level 2</u>** | **<u>Level 3</u>** | **<u>Total</u>** |
| <u>Investments:</u> |  |  |  |  |
|  &nbsp;&nbsp;&nbsp;&nbsp;Common Stocks | $9475252 | $– | $– | $9475252 |
|  &nbsp;&nbsp;&nbsp;&nbsp;Money Market Funds | 220990 | – | – | 220990 |
| Total Investments | $9696242 | $– | $– | $9696242 |
| Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. |

---

---

| | | |
|:---|:---|:---|
| **Allocation of Portfolio Holdings by Country as of May 31, 2025** | **Allocation of Portfolio Holdings by Country as of May 31, 2025** | |
| (% of Net Assets) | (% of Net Assets) |  |
| United States | $7278739 | 74.9% |
| Ireland | 638616 | 6.6 |
| Netherlands | 510201 | 5.3 |
| Israel | 484287 | 5.0 |
| Belgium | 216599 | 2.2 |
| Canada | 176302 | 1.8 |
| Japan | 161846 | 1.7 |
| Germany | 131958 | 1.4 |
| Finland | 97694 | 1.0 |
| Other Assets in Excess of Liabilities | 14353 | 0.1 |
|  | $**9710595** | 100.0<br> **%** |

---

---

| | | |
|:---|:---|:---|
| **Sector Classification as of May 31, 2025** | **Sector Classification as of May 31, 2025** | |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(% of Net Assets) |  |  |
| Health Care | $9475252 | 97.6% |
| Money Market Funds | 220990 | 2.3 |
| Other Assets in Excess of Liabilities | 14353 | 0.1 |
|  | **9710595** | 100.0<br> **%** |

---

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** Tema ETF Trust

- **b. Investment Company Act file number:** 811-23823

- **c. CIK number of Registrant:** 0001944285

- **d. LEI of Registrant:** 549300JKGDXNE2CLUY37

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 200 Vesey Street

  - **City:** New York

  - **State:** NY

  - **Foreign country:** US

  - **Zip / Postal Code:** 10281

  - **Telephone number:** 3024994928 EXT 801

**Item A.2. Information about the Series.**

- **a. Name of Series:** Tema Neuroscience and Mental Health ETF

- **b. EDGAR series identifier (if any):** S000081543

- **c. LEI of Series:** 529900GTKXSMAKOECZ04

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-02-28

- **b. Date as of which information is reported:** 2025-05-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $9716914.02

**Total Liabilities:** $6318.71

**Net Assets:** $9710595.31

**Cash Not Reported:** $15550.16

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000244457 | -7.20%               | 0.55%                | -4.84%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $134029.64               | $-919135.67                                |
| Month 2  | $30.10                   | $58380.40                                  |
| Month 3  | $35.88                   | $-490409.03                                |

**Designated Index Information**

- **Index Name:** N/A

- **Index Identifier:** N/A

### Schedule of Portfolio Investments

| Name                           | Title                                    | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| ACADIA Pharmaceuticals Inc     | ACADIA Pharmaceuticals Inc               | CUSIP: 004225108<br>LEI: 529900O3044NO0PEA039 | Long             | EC               | CORP              | US        |     10596 | NS      | $228555.72    | 2.35%             |  |  |  | No            |                  1 | On Loan: No      |
| Alnylam Pharmaceuticals Inc    | Alnylam Pharmaceuticals Inc              | CUSIP: 02043Q107<br>LEI: 529900S3ZI14OWRJII50 | Long             | EC               | CORP              | US        |      1982 | NS      | $603637.92    | 6.22%             |  |  |  | No            |                  1 | On Loan: No      |
| Argenx SE                      | Argenx SE                                | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             | EC               | CORP              | NL        |       890 | NS      | $510201.40    | 5.25%             |  |  |  | No            |                  1 | On Loan: No      |
| Catalyst Pharmaceuticals Inc   | Catalyst Pharmaceuticals Inc             | CUSIP: 14888U101<br>LEI: 5299004O0R5XXLA5H544 | Long             | EC               | CORP              | US        |     11352 | NS      | $283345.92    | 2.92%             |  |  |  | No            |                  1 | On Loan: No      |
| Crinetics Pharmaceuticals Inc  | Crinetics Pharmaceuticals Inc            | CUSIP: 22663K107<br>LEI: 549300Q1CNFXK5P31D28 | Long             | EC               | CORP              | US        |     13066 | NS      | $398643.66    | 4.11%             |  |  |  | No            |                  1 | On Loan: No      |
| First American Treasury Obliga | First American Treasury Obligations Fund | CUSIP: 31846V328<br>LEI: 549300UU586IAH2B8H03 | Long             | STIV             | RF                | US        |    220990 | NS      | $220989.80    | 2.28%             |  |  |  | No            |                  1 | On Loan: No      |
| Ionis Pharmaceuticals Inc      | Ionis Pharmaceuticals Inc                | CUSIP: 462222100<br>LEI: 549300SI4ZGLG0BLUZ92 | Long             | EC               | CORP              | US        |      8318 | NS      | $278736.18    | 2.87%             |  |  |  | No            |                  1 | On Loan: No      |
| UCB SA                         | UCB SA                                   | CUSIP: N/A<br>LEI: 2138008J191VLSGY5A09       | Long             | EC               | CORP              | BE        |      1193 | NS      | $216598.77    | 2.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Sysmex Corp                    | Sysmex Corp                              | CUSIP: N/A<br>LEI: 5299001ZO4CKWACMZI55       | Long             | EC               | CORP              | JP        |      6108 | NS      | $103253.83    | 1.06%             |  |  |  | No            |                  1 | On Loan: No      |
| Rapport Therapeutics Inc       | Rapport Therapeutics Inc                 | CUSIP: 75383L102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1499 | NS      | $12396.73     | 0.13%             |  |  |  | No            |                  1 | On Loan: No      |
| Talkspace Inc                  | Talkspace Inc                            | CUSIP: 87427V103<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     27834 | NS      | $88790.46     | 0.91%             |  |  |  | No            |                  1 | On Loan: No      |
| Day One Biopharmaceuticals Inc | Day One Biopharmaceuticals Inc           | CUSIP: 23954D109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     11305 | NS      | $72125.90     | 0.74%             |  |  |  | No            |                  1 | On Loan: No      |
| Teva Pharmaceutical Industries | Teva Pharmaceutical Industries Ltd       | CUSIP: 881624209<br>LEI: 549300BAFGM4RC74ZJ94 | Long             | EC               | CORP              | IL        |     28861 | NS      | $484287.58    | 4.99%             |  |  |  | No            |                  1 | On Loan: No      |
| Prothena Corp PLC              | Prothena Corp PLC                        | CUSIP: N/A<br>LEI: 5299009ZXQ8NIIJ8OL30       | Long             | EC               | CORP              | IE        |      6351 | NS      | $29151.09     | 0.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Acadia Healthcare Co Inc       | Acadia Healthcare Co Inc                 | CUSIP: 00404A109<br>LEI: 5493005CW985Y9D0NC11 | Long             | EC               | CORP              | US        |      2596 | NS      | $58773.44     | 0.61%             |  |  |  | No            |                  1 | On Loan: No      |
| Arvinas Inc                    | Arvinas Inc                              | CUSIP: 04335A105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      2074 | NS      | $14932.80     | 0.15%             |  |  |  | No            |                  1 | On Loan: No      |
| Avidity Biosciences Inc        | Avidity Biosciences Inc                  | CUSIP: 05370A108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      5392 | NS      | $167044.16    | 1.72%             |  |  |  | No            |                  1 | On Loan: No      |
| Axsome Therapeutics Inc        | Axsome Therapeutics Inc                  | CUSIP: 05464T104<br>LEI: 549300EXGR0XLRJEIB95 | Long             | EC               | CORP              | US        |      2327 | NS      | $244707.32    | 2.52%             |  |  |  | No            |                  1 | On Loan: No      |
| Stryker Corp                   | Stryker Corp                             | CUSIP: 863667101<br>LEI: 5493002F0SC4JTBU5137 | Long             | EC               | CORP              | US        |       798 | NS      | $305346.72    | 3.14%             |  |  |  | No            |                  1 | On Loan: No      |
| Xenon Pharmaceuticals Inc      | Xenon Pharmaceuticals Inc                | CUSIP: 98420N105<br>LEI: 549300XV44Q9Z1MIPQ03 | Long             | EC               | CORP              | CA        |      6111 | NS      | $176302.35    | 1.82%             |  |  |  | No            |                  1 | On Loan: No      |
| Orion Oyj                      | Orion Oyj                                | CUSIP: N/A<br>LEI: 74370029VAHCXDR7B745       | Long             | EC               | CORP              | FI        |      1440 | NS      | $97693.91     | 1.01%             |  |  |  | No            |                  1 | On Loan: No      |
| Alkermes PLC                   | Alkermes PLC                             | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | IE        |      5940 | NS      | $181823.40    | 1.87%             |  |  |  | No            |                  1 | On Loan: No      |
| Biohaven Ltd                   | Biohaven Ltd                             | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | US        |      3831 | NS      | $56737.11     | 0.58%             |  |  |  | No            |                  1 | On Loan: No      |
| Jazz Pharmaceuticals PLC       | Jazz Pharmaceuticals PLC                 | CUSIP: N/A<br>LEI: 635400GAUMJCLEZRRV50       | Long             | EC               | CORP              | IE        |      1672 | NS      | $180693.04    | 1.86%             |  |  |  | No            |                  1 | On Loan: No      |
| Medtronic PLC                  | Medtronic PLC                            | CUSIP: N/A<br>LEI: 549300GX3ZBSQWUXY261       | Long             | EC               | CORP              | IE        |      2976 | NS      | $246948.48    | 2.54%             |  |  |  | No            |                  1 | On Loan: No      |
| Neurocrine Biosciences Inc     | Neurocrine Biosciences Inc               | CUSIP: 64125C109<br>LEI: 549300FECER0XBN49756 | Long             | EC               | CORP              | US        |      3904 | NS      | $480270.08    | 4.95%             |  |  |  | No            |                  1 | On Loan: No      |
| Penumbra Inc                   | Penumbra Inc                             | CUSIP: 70975L107<br>LEI: 549300RGE06P3ECANU72 | Long             | EC               | CORP              | US        |       617 | NS      | $164720.49    | 1.70%             |  |  |  | No            |                  1 | On Loan: No      |
| Regeneron Pharmaceuticals Inc  | Regeneron Pharmaceuticals Inc            | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |      1284 | NS      | $629519.52    | 6.48%             |  |  |  | No            |                  1 | On Loan: No      |
| Denali Therapeutics Inc        | Denali Therapeutics Inc                  | CUSIP: 24823R105<br>LEI: 549300ZTQ2HO18L3Q830 | Long             | EC               | CORP              | US        |     15174 | NS      | $200903.76    | 2.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Eisai Co Ltd                   | Eisai Co Ltd                             | CUSIP: N/A<br>LEI: 353800HDEE0ZYEX4QV91       | Long             | EC               | CORP              | JP        |      2036 | NS      | $58591.86     | 0.60%             |  |  |  | No            |                  1 | On Loan: No      |
| Vertex Pharmaceuticals Inc     | Vertex Pharmaceuticals Inc               | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |      2298 | NS      | $1015830.90   | 10.46%            |  |  |  | No            |                  1 | On Loan: No      |
| Siemens Healthineers AG        | Siemens Healthineers AG                  | CUSIP: N/A<br>LEI: 529900QBVWXMWANH7H45       | Long             | EC               | CORP              | DE        |      2495 | NS      | $131958.42    | 1.36%             |  |  |  | No            |                  1 | On Loan: No      |
| Option Care Health Inc         | Option Care Health Inc                   | CUSIP: 68404L201<br>LEI: 549300DI3Q5ACSYJRI17 | Long             | EC               | CORP              | US        |      4975 | NS      | $162583.00    | 1.67%             |  |  |  | No            |                  1 | On Loan: No      |
| Praxis Precision Medicines Inc | Praxis Precision Medicines Inc           | CUSIP: 74006W207<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1055 | NS      | $40670.25     | 0.42%             |  |  |  | No            |                  1 | On Loan: No      |
| Scholar Rock Holding Corp      | Scholar Rock Holding Corp                | CUSIP: 80706P103<br>LEI: 549300Z1FLPGL4OWJ459 | Long             | EC               | CORP              | US        |      4836 | NS      | $140292.36    | 1.44%             |  |  |  | No            |                  1 | On Loan: No      |
| Immunovant Inc                 | Immunovant Inc                           | CUSIP: 45258J102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      5866 | NS      | $87110.10     | 0.90%             |  |  |  | No            |                  1 | On Loan: No      |
| Eli Lilly & Co                 | Eli Lilly & Co                           | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |       547 | NS      | $403505.49    | 4.16%             |  |  |  | No            |                  1 | On Loan: No      |
| Biogen Inc                     | Biogen Inc                               | CUSIP: 09062X103<br>LEI: W8J5WZB5IY3K0NDQT671 | Long             | EC               | CORP              | US        |      2501 | NS      | $324604.79    | 3.34%             |  |  |  | No            |                  1 | On Loan: No      |
| Dexcom Inc                     | Dexcom Inc                               | CUSIP: 252131107<br>LEI: 549300YSK3QDSFR5EU59 | Long             | EC               | CORP              | US        |      2231 | NS      | $191419.80    | 1.97%             |  |  |  | No            |                  1 | On Loan: No      |
| Dyne Therapeutics Inc          | Dyne Therapeutics Inc                    | CUSIP: 26818M108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      4717 | NS      | $56415.32     | 0.58%             |  |  |  | No            |                  1 | On Loan: No      |
| Intellia Therapeutics Inc      | Intellia Therapeutics Inc                | CUSIP: 45826J105<br>LEI: 5493002T5BCPE5DZC723 | Long             | EC               | CORP              | US        |      7677 | NS      | $52740.99     | 0.54%             |  |  |  | No            |                  1 | On Loan: No      |
| Sarepta Therapeutics Inc       | Sarepta Therapeutics Inc                 | CUSIP: 803607100<br>LEI: 549300IKDPIED8J8IG21 | Long             | EC               | CORP              | US        |      1943 | NS      | $73056.80     | 0.75%             |  |  |  | No            |                  1 | On Loan: No      |
| Solid Biosciences Inc          | Solid Biosciences Inc                    | CUSIP: 83422E204<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      8649 | NS      | $27763.29     | 0.29%             |  |  |  | No            |                  1 | On Loan: No      |
| Voyager Therapeutics Inc       | Voyager Therapeutics Inc                 | CUSIP: 92915B106<br>LEI: 54930082S4XVR0ZWCC74 | Long             | EC               | CORP              | US        |     14960 | NS      | $40990.40     | 0.42%             |  |  |  | No            |                  1 | On Loan: No      |
| PTC Therapeutics Inc           | PTC Therapeutics Inc                     | CUSIP: 69366J200<br>LEI: 549300UJLWOIWFDGB318 | Long             | EC               | CORP              | US        |      3124 | NS      | $151576.48    | 1.56%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2025-07-23

**Name of Applicant:** Tema ETF Trust

**Signature:** /s/ Josh Hunter

**Name of Signer:** Josh Hunter

**Title:** Treasurer